Search

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

UBC launches Canada's first graduate blockchain training path

Dr. Todd Duffield named as the 2018 Metacam® 20* Bovine Welfare Award winner

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

Accessible Customer Service Policy

Accessibility Plan

Twenty years of controlling Lawsonia intracellularis

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

UBC launches Canada's first graduate blockchain training path

Dr. Todd Duffield named as the 2018 Metacam® 20* Bovine Welfare Award winner

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

Accessible Customer Service Policy

Accessibility Plan

Twenty years of controlling Lawsonia intracellularis

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 